# Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension

> **NCT00702221** · PHASE2 · TERMINATED · sponsor: **BTG International Inc.** · enrollment: 20 (actual)

## Conditions studied

- Hypertension
- Cardiovascular Disease

## Interventions

- **BIOLOGICAL:** Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant
- **BIOLOGICAL:** CoVaccine HT™ adjuvant

## Key facts

- **NCT ID:** NCT00702221
- **Lead sponsor:** BTG International Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2009-06
- **Final completion:** 2010-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Dose limiting adverse effects
- **Last updated:** 2016-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702221, "Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00702221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*